Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer

被引:66
|
作者
Aletti, Giovanni D. [1 ]
Dowdy, Sean [1 ]
Podratz, Karl C. [1 ]
Cliby, William A. [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Dept Obstet & Gynecol, Rochester, MN 55905 USA
关键词
lymphadenectomy; cytoreduction; node metastasis; ovarian cancer;
D O I
10.1016/j.ajog.2006.06.068
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The purpose of this study was to determine the factors that are related to the performance of lymph node assessment and its impact on prognosis in ovarian cancer. Study design: This was a retrospective analysis of stage IIIC/IV epithelial ovarian cancer in patients who had undergone primary surgery between 1994 and 1998. Simple statistics and univariate and multivariable analysis were performed. Results: Two hundred nineteen patients met the inclusion criteria; lymph node assessment was performed for 93 of these patients (41%). Sixty-one patients (65.5%) underwent complete pelvic and para-aortic lymphadenectomy, and 32 patients (34.5%) underwent a more limited lymph node sampling. In patients with residual disease > 1 cm, lymph node assessment was an independent predictor of outcome. In this same subgroup, lymphadenectomy appeared to be superior to lymph node sampling (5-year overall survival, 50% (lymphadenectomy) vs 33% (lymph node sampling) vs 29% (no lymph node assessment); P =.01). Considering survival of the subgroup who underwent lymph node assessment, we observed a significantly worse outcome for those with lymphatic involvement (5-year overall survival, 31.5% [positive for nodal metastases] vs 54% [negative for nodal metastases]; P =.003). Although multiple factors were correlated with the decision to perform lymph node assessment in univariate analysis, only the surgeon (P <.001), low residual disease (P =.004), American Society of Anesthesiology I or 2 (P =.004), and the absence of carcinomatosis (P =.0002) were independent factors in the multivariable analysis. Further, if lymph node assessment was performed, the decision to do lymphadenectomy versus lymph node sampling was associated independently with the surgeon (P <.001), low residual disease (P <.001), and patient age of < 65 years (P <.001). Conclusion: Removal of obviously involved lymph nodes in patients with residual disease near 1 cm and lymphadenectomy for patients with complete or near complete resection of abdominal disease appears to be justified. A lack of standard recommendation in advanced ovarian cancer results in wide variations that are based on individual preference in addition to logical factors. (c) 2006 Mosby, Inc. All rights reserved.
引用
收藏
页码:1862 / 1868
页数:7
相关论文
共 50 条
  • [1] Management of retroperitoneal lymphadenectomy in advanced epithelial ovarian cancer
    Jaffre, I.
    Bordes, V.
    Dejode, M.
    Dravet, F.
    Classe, J. -M.
    [J]. BULLETIN DU CANCER, 2010, 97 (01) : 65 - 71
  • [2] SURVIVAL ROLE OF LYMPHADENECTOMY IN PATIENTS SURGICALLY TREATED FOR APPARENT EARLY-STAGE EPITHELIAL OVARIAN CANCER
    Lembo, A.
    Dri, M.
    Longo, M.
    Oltolina, N.
    Riva, M.
    Artuso, V.
    Ghezzi, F.
    Casarin, J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A79 - A80
  • [3] THERAPEUTIC ROLE OF PELVIC AND PARA-AORTIC LYMPHADENECTOMY IN APPARENT EARLY STAGE EPITHELIAL OVARIAN CANCER
    Bizzarri, N.
    Corrado, G.
    Cianci, S.
    Ergasti, R.
    Perri, M. T.
    Rumolo, V.
    Rosati, A.
    Ghirardi, V.
    Pasciuto, T.
    Scambia, G.
    Fagotti, A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A441 - A441
  • [4] THERAPEUTIC ROLE OF PELVIC AND PARA-AORTIC LYMPHADENECTOMY IN APPARENT EARLY STAGE EPITHELIAL OVARIAN CANCER
    Bizzarri, N.
    Du Bois, A.
    Fruscio, R.
    De Felice, F.
    De Iaco, P.
    Casarin, J.
    Vizza, E.
    Chiantera, V.
    Corrado, G.
    Cianci, S.
    Harter, P.
    Ataseven, B.
    Bommert, M.
    Perrone, A. M.
    Magni, S.
    Ferrari, D.
    Zambetti, B.
    Scambia, G.
    Fagotti, A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A19 - A20
  • [5] Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
    Bizzarri, Nicolo
    du Bois, Andreas
    Fruscio, Robert
    De Felice, Francesca
    De Iaco, Pierandrea
    Casarin, Jvan
    Vizza, Enrico
    Chiantera, Vito
    Corrado, Giacomo
    Cianci, Stefano
    Magni, Sonia
    Ferrari, Debora
    Giuliani, Daniela
    Harter, Philipp
    Ataseven, Beyhan
    Bommert, Mareike
    Perrone, Anna Myriam
    Scambia, Giovanni
    Fagotti, Anna
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 160 (01) : 56 - 63
  • [6] Lymphadenectomy in surgical stage I epithelial ovarian cancer
    Svolgaard, Olivia
    Lidegaard, Ojvind
    Nielsen, Marie Louise S.
    Nedergaard, Lotte
    Mosgaard, Berit J.
    Lidang, Marianne
    Mogensen, Ole
    Kock, Kirsten
    Blaakaer, Jan
    Staehr, Estrid
    Andersen, Erik S.
    Grove, Anni
    Hogdall, Claus
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2014, 93 (03) : 256 - 260
  • [7] Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature
    Desteli, Guldeniz Aksan
    Gultekin, Murat
    Usubutun, Alp
    Yuce, Kunter
    Ayhan, Ali
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2010, 8
  • [8] Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature
    Guldeniz Aksan Desteli
    Murat Gultekin
    Alp Usubutun
    Kunter Yuce
    Ali Ayhan
    [J]. World Journal of Surgical Oncology, 8
  • [9] Lymph Node Metastasis in Grossly Apparent Stages I and II Epithelial Ovarian Cancer
    Nomura, Hiroyuki
    Tsuda, Hiroshi
    Susumu, Nobuyuki
    Fujii, Takuma
    Banno, Kouji
    Kataoka, Fumio
    Tominaga, Eiichiro
    Suzuki, Atsushi
    Chiyoda, Tatsuyuki
    Aoki, Daisuke
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (03) : 341 - 345
  • [10] WHAT IS THE PROGNOSTIC VALUE OF LYMPHADENECTOMY IN ADVANCED EPITHELIAL OVARIAN CANCER?
    Zemni, I.
    Mansouri, H.
    Ben Safta, I.
    Boujelbene, N.
    Ben Hassouna, J.
    Hechiche, M.
    Chargui, R.
    Rahal, K.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A120 - A121